Clinical trial data indicated the drug Xofigo, which emits radioactive particles, may increase survival and improve quality of life for men whose advanced prostate cancer has spread to the bones, U.K. researchers reported in the New England Journal of Medicine. Patients lived four months, or 30%, longer with the drug, which was approved by the FDA in May, compared with a placebo.

Full Story:
HealthDay News

Related Summaries